tiprankstipranks
Annovis Bio Gains FDA Nod for Buntanetap Crystal Form
Company Announcements

Annovis Bio Gains FDA Nod for Buntanetap Crystal Form

Pick the best stocks and maximize your portfolio:

Annovis Bio (ANVS) has provided an update.

Annovis Bio, Inc. has received FDA approval to use a new crystal form of Buntanetap in upcoming clinical trials, marking a significant step forward for the company’s drug development efforts. This advancement is expected to intrigue those watching biotech stocks and could potentially influence the company’s market position.

See more insights into ANVS stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAnnovis Bio Advances Alzheimer’s and Parkinson’s Drug Trials
TipRanks Auto-Generated NewsdeskAnnovis Bio Appoints William Fricker as Interim CFO
TheFlyAnnovis sees cash runway for Phase 3 preparatory studies, entering AD study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App